Virtual Library
Start Your Search
Amina Iraqi
Author of
-
+
EP1.14 - Targeted Therapy (ID 204)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Targeted Therapy
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.14-40 - Locally Advanced Desmoide Tumor: Response to Sorafenib: Case Report (Now Available) (ID 1140)
08:00 - 18:00 | Author(s): Amina Iraqi
- Abstract
Background
Desmoid tumors or deep fibromatoses are malignant connective clonal tissue tumors that do not metastasize, but are at high risk of local recurrence and are associated with morbidity and mortality. There is still no standard for treatment, however the reactions of patients with desmoid tumors with Sorafenib are promising. The objective of this work is to highlight the contribution of sorafenib in the treatment of desmoid tumors.
Method
Our study is a case report conducted in the oncology department of IBN ROCHD CHU of Casablanca, focusing on the analysis of the Sorafenib response in patient with locally advanced desmoid tumor.
Result
Our case is a 60-year-old patient with no comorbidities who had presented in 2012 a left dorsal parietal mass, he was operated on, the histopathological examination concluded to a desmoid tumor. He presented in 2015 a tumor recurrence for which he was again operated and put under Celecoxib for one year, after the clinical and radiological progression, he was put under Tamoxifen, for 2 years. Currently, he presents a tumor increase. In fact he has a posterior dorso lumbar parietal mass, measuring clinically about 15 cm, very painful, the initial thoracic CT scan as well as the MRI of the soft tissues showed left lateral vertebral parietal mass, hypodense coming into contact with the last 3 ribs without bone lysis, measuring 12 * 11 * 7 cm. The surgery was considered dilapidated by the surgeons, the decision was to put the patient under Sorafenib 400 mg per day, the assessment after two months found an excellent clinical and radiological response, with a total disappearance of pain and 50% decrease in the size of the initial injury on the chest CT scan.
Conclusion
This case study allowed us to support the efficacy of Sorafenib, currently being tested (Study Alliance A91105) in the treatment of recurrent or locally advanced desmoid tumors.
